TY - JOUR
T1 - Human T-cells recognise N-terminally Fmoc-modified peptide
AU - Mannering, Stuart I.
AU - Purcell, Anthony W.
AU - Honeyman, Margo C.
AU - McCluskey, James
AU - Harrison, Leonard C.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - We aimed to generate T-cell clones specific for human pre-proinsulin. An HLA DQ8, CD4+ T-cell clone that recognised a 10mer (C65-A9) peptide from pre-proinsulin was isolated. Further analysis revealed that the clone responded neither to recombinant proinsulin nor to re-synthesised C65-A9 peptide. Analysis of the original peptide revealed minor contamination (<0.5%) with an N-terminal Fmoc adduct. This peptide was synthesised and shown to stimulate the clone. Thus, Fmoc-modified peptides, which are common contaminants in synthetic peptides, can stimulate human CD4+ T-cells. This finding has important implications for the use of synthetic peptides in screening and epitope mapping studies and their use as vaccines in humans.
AB - We aimed to generate T-cell clones specific for human pre-proinsulin. An HLA DQ8, CD4+ T-cell clone that recognised a 10mer (C65-A9) peptide from pre-proinsulin was isolated. Further analysis revealed that the clone responded neither to recombinant proinsulin nor to re-synthesised C65-A9 peptide. Analysis of the original peptide revealed minor contamination (<0.5%) with an N-terminal Fmoc adduct. This peptide was synthesised and shown to stimulate the clone. Thus, Fmoc-modified peptides, which are common contaminants in synthetic peptides, can stimulate human CD4+ T-cells. This finding has important implications for the use of synthetic peptides in screening and epitope mapping studies and their use as vaccines in humans.
KW - Fmoc
KW - Peptides
KW - T lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=0242380659&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(03)00402-X
DO - 10.1016/S0264-410X(03)00402-X
M3 - Article
C2 - 12922093
AN - SCOPUS:0242380659
VL - 21
SP - 3638
EP - 3646
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 25-26
ER -
